Table 1 |
||||||||||||||
|
Summary of the studies assessing P-cadherin expression in invasive breast cancer |
||||||||||||||
|
Ref. |
P-cadherin positive expression in breast cancer (n [%]) |
Tumour size |
Axillary lymph node metastasis |
Histological grade |
ER |
PgR |
HER2 |
MIB1 |
EGFR |
Basal CKs |
p53 |
Patient overall survival |
Independent prognostic factor |
IHC P-cadherin mAb |
|
|
||||||||||||||
|
[36] |
1/25 (4%) |
ND |
ND |
ND |
ND |
ND |
ND |
ND |
ND |
ND |
ND |
ND |
ND |
NCC-CAD-299 (Takeichi gift) |
|
[35] |
9/45 (20%) |
NS |
NS |
+ (P < 0.01) |
- (P < 0.01) |
- (P < 0.05) |
ND |
ND |
ND |
NS |
ND |
ND |
ND |
NCC-CAD-299 (Takeichi gift) |
|
[47] |
95/183 (52%) |
NS |
NS |
+ (P = 0.0006) |
- (P < 0.0001) |
- (P < 0.0001) |
ND |
ND |
ND |
ND |
ND |
+ (P = 0.0001) |
Yes |
Clone 56 (Transduction) |
|
[53] |
36/51 (71%) |
ND |
NS |
ND |
ND |
ND |
ND |
ND |
ND |
ND |
ND |
- (P = 0.05) |
Yes |
N-19 pAb (Santa Cruz) |
|
[48] |
74/210 (35%) |
+ (P = 0.0568) |
+ (P = 0.0327) |
+ (P = 0.0001) |
- (P = 0.0001) |
- (P = 0.0001) |
ND |
ND |
ND |
ND |
ND |
+ (P = 0.004) |
No |
Clone 56 (Transduction) |
|
[51] |
40/100 (40%) |
NS |
NS |
+ (P < 0.005) |
- (P < 0.001) |
- (P < 0.025) |
ND |
ND |
+ (P < 0.001) |
ND |
ND |
ND |
ND |
Clone 56 (Transduction) |
|
[57] |
80/261 (31%) |
+ (P = 0.05) |
NS |
+ (P < 0.0001) |
- (P < 0.001) |
ND |
+ (P = 0.04) |
ND |
ND |
+ (P < 0.001) |
+ (P < 0.0001) |
+ (P < 0.0001) |
No |
Clone 56 (Transduction) |
|
[44] |
46/147 (31%) |
NS |
NS |
+ (P = 0.0021) |
- (P < 0.0001) |
ND ND |
+ (P = 0.0036) |
+ (P = 0.0002) |
ND ND |
ND ND |
+ (P = 0.0064) |
+ (P = 0.0237) |
ND |
Clone 56 (Transduction) |
|
|
||||||||||||||
|
Summary of the results obtained in studies that assessed the prevalence of P-cadherin expression in invasive breast carcinomas and its correlation with various factors: tumour size, axillary lymph node metastasis, histological grade, levels of oestrogen receptor (ER), progesterone receptor (PgR), human epidermal growth factor receptor (HER)2, MIB1, epidermal growth factor receptor (EGFR), basal cytokeratins (CKs) and p53 expression, and patient survival. Information concerning whether P-cadherin was considered to be an independent predictor of outcome and about the monoclonal antibody (mAb) used in the immunohistochemistry (IHC) analysis is also included. +, direct significant correlation; -, inverse significant correlation; ND, not determined; NS, no significant correlation. |
||||||||||||||
|
Paredes et al. Breast Cancer Research 2007 9:214 doi:10.1186/bcr1774 |
||||||||||||||